APi
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
APi Group Corporation operates as a global enterprise offering vital safety, specialized infrastructure, and industrial services across North America, Europe, Australia, and the Asia-Pacific region. I...
Latest News
8 days ago · zacks.com
Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year?Here is how APi (APG) and Healthcare Services (HCSG) have performed compared to their sector so far this year.
10 days ago · zacks.com
APi (APG) is an Incredible Growth Stock: 3 Reasons WhyAPi (APG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
11 days ago · zacks.com
Wall Street Analysts See a 36.62% Upside in APi (APG): Can the Stock Really Move This High?The consensus price target hints at a 36.6% upside potential for APi (APG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
12 days ago · globenewswire.com
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that multiple clinical and preclinical studies have been selected at the 68th American Society of Hematology (ASH) Annual Meeting, involving four of the Company's proprietary innovative drug candidates, namely olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China, lisaftoclax (APG-2575), a potentially best-in-class Bcl-2 inhibitor approved in China, APG-5918, a PRC2/EED inhibitor, and APG-3288, a BTK protein degrader. These new data presentations highlight the Company's global innovation capabilities in hematologic malignancies. Notably, APG-5918 was selected for an oral presentation upon the first disclosure of its clinical data.
15 days ago · zacks.com
What Makes APi (APG) a Strong Momentum Stock: Buy Now?Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out.
18 days ago · marketbeat.com
What APi Group (APG) Said on Its Q3 Earnings CallAPi Group NYSE: APG reported record third-quarter results, with revenue rising 22.5% year over year to $2.55 billion and organic revenue growth of 15.7%, as demand remained strong across inspection, service, monitoring and project work.
18 days ago · seekingalpha.com
APi Group Corporation (APG) Q3 2026 Earnings Call TranscriptAPi Group Corporation (APG) Q3 2026 Earnings Call Transcript
19 days ago · zacks.com
APi (APG) Tops Q3 Earnings and Revenue EstimatesAPi (APG) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.41 per share a year ago.
19 days ago · zacks.com
Here's What Key Metrics Tell Us About APi (APG) Q3 EarningsThe headline numbers for APi (APG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
19 days ago · businesswire.com
APi Group Reports Record Third Quarter 2026 Financial Results and Raises Full-Year 2026 OutlookNEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2026. Russ Becker, APi's President and Chief Executive Officer, stated: “We delivered exceptional third quarter results, including double digit organic growth and adjusted EBITDA margin expansion. This performance again demonstrates the durability of our business in a dynamic operating environment. Strong demand a.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove APG